Methotrexate Weekly Dosing Guidelines

Rheumatoid Arthritis (RA) – Initial and Titration Dosing

Start oral methotrexate at 10–15 mg once weekly; increase by 5 mg every 2–4 weeks to a target of 20–30 mg/week based on clinical response and tolerability. 1
The 2021 American College of Rheumatology (ACR) guidelines conditionally recommend titrating to ≥15 mg/week within 4–6 weeks to optimise efficacy. 2
In patients with normal renal function, an initial dose of 15 mg/week is reasonable; a lower test dose of 2.5–5 mg should be used for those with renal impairment, advanced age, or interacting medications. 3, 4

Psoriasis – Initial and Maintenance Dosing

Recommended weekly dose range is 7.5–25 mg, administered either as a single dose or divided into three doses over 24 hours. 5
The NICE guideline advises starting at 5–10 mg/week with gradual increments up to a maximum of 25 mg/week; more aggressive regimens may begin at 15 mg/week in suitable patients. 6

Dose Escalation Strategies

Rapid escalation (5 mg/month up to 25–30 mg/week) yields higher efficacy but increases adverse events compared with slow escalation (5 mg every 3 months). 1
Initiating therapy at 25 mg/week is more effective than 15 mg/week but is associated with a higher rate of gastrointestinal toxicity. 1
For psoriasis, dose adjustments typically require ≥4 weeks to observe clinical response. 3, 7

Maximum Dose Considerations

The standard maximum dose for both RA and psoriasis is 25 mg/week. 5, 6
Selected RA patients may be escalated to 30 mg/week according to certain guidelines. 1

Route of Administration

Oral methotrexate is preferred initially; switch to subcutaneous (or intramuscular) formulation when any of the following occur: inadequate clinical response, gastrointestinal intolerance, poor adherence, or when doses exceed 20 mg/week (bioavailability concerns). 1, 2, 5, 6
The 2021 ACR guidelines conditionally recommend transitioning to subcutaneous methotrexate rather than adding or switching to another DMARD when oral therapy fails to achieve target response. 2
Parenteral administration provides higher bioavailability and may reduce gastrointestinal toxicity. 1

Folic Acid Supplementation

≥5 mg folic acid per week is strongly recommended to mitigate methotrexate toxicity. 1
The preferred regimen is daily folic acid on days other than the methotrexate dose day. 3, 8
Supplementation reduces hepatic abnormalities and gastrointestinal adverse effects. 5, 3
No proven efficacy difference exists between folic acid and folinic acid; folic acid is less costly. 5, 8
Very high folic acid doses may diminish methotrexate efficacy. 5

Monitoring Requirements

Baseline labs before initiating therapy: complete blood count (CBC), liver enzymes (AST/ALT), albumin, serum creatinine, and a chest radiograph (within the past year); consider hepatitis B/C serology, HIV testing, fasting glucose, lipid profile, and pregnancy testing as appropriate. 1, 9
During therapy for RA: CBC, liver function tests, and creatinine every 1–1.5 months until a stable dose is reached, then every 1–3 months thereafter. 9
For psoriasis, monitoring can be spaced to every 3–6 months once the dose is stable. 5

Safety Considerations

Methotrexate must be administered weekly, not daily; dosing errors are a major cause of toxicity. 7
Discontinue methotrexate if ALT or AST rise > 3 × the upper limit of normal on confirmed repeat testing. 1, 9
Methotrexate is contraindicated in pregnancy; it should be stopped ≥3 months before planned conception for both men and women. 1, 9

Methotrexate Monitoring and Hepatotoxicity Management in Psoriasis

Routine Laboratory Monitoring

The American Academy of Dermatology recommends checking liver function tests (LFTs) every 3–6 months during stable methotrexate therapy when prior results are normal. 10, 11, 12
During the first month of therapy and until a steady dosing regimen is achieved, LFTs should be obtained every 1–2 weeks. 13
After any dose increase, clinicians should perform closer monitoring because hepatotoxicity may appear as late as 6 weeks post‑adjustment. 14, 12

Action When LFTs Are Abnormal

Any abnormal LFT elevation should trigger a repeat test in 2–4 weeks to confirm persistence. 10, 11, 12
If the abnormality persists on repeat testing, a gastroenterology/hepatology referral is advised. 10, 11, 12
The guidelines emphasize that no specific “acceptable” transaminase threshold exists; the presence of any abnormality initiates the above steps. 10, 11

Baseline Hepatic Assessment (Patients Without Recognized Risk Factors)

Before initiating methotrexate, a non‑invasive liver fibrosis assessment (e.g., transient elastography) is recommended. 10, 11
Baseline liver biopsy is not recommended, irrespective of risk‑factor status. 10, 11
If the baseline fibrosis assessment is normal, patients proceed with the routine 3–6 month LFT schedule. 10, 11

Identification of High‑Risk Patients

High‑risk features include:
For patients with these risk factors, clinicians should consider alternative systemic therapies to methotrexate. 10, 11
If methotrexate is still chosen, abnormal baseline fibrosis results should prompt referral to gastroenterology/hepatology or performance of vibration‑controlled transient elastography. 10, 11, 14
Methotrexate may be continued only when the estimated risk of cirrhosis is low based on the baseline assessment. 10, 11
In high‑risk patients who remain on methotrexate despite abnormal baseline findings, an annual gastroenterology/hepatology evaluation or repeat transient elastography is advised. 10, 11

Folic Acid Supplementation

The American Academy of Dermatology strongly recommends daily folic acid supplementation (taken on days other than the methotrexate dose) to mitigate hepatic adverse effects. 10, 15
Evidence from the British Association of Dermatology indicates that folic acid reduces both hepatic laboratory abnormalities and gastrointestinal side‑effects. 13

Methotrexate Dose Escalation and Monitoring in Psoriasis (British Journal of Dermatology)

Dose‑titration Recommendations

For patients with psoriasis, methotrexate should be increased stepwise to a maximum of 25 mg per week during escalation, as outlined in the British Journal of Dermatology. 16

Safety‑monitoring Guidance

During methotrexate therapy, clinicians must vigilantly monitor for toxicity signs such as fever, oral (mouth) ulcers, unexplained bruising, persistent nausea, and breathlessness; these adverse‑event indicators are highlighted in the British Journal of Dermatology. 16

Expected Therapeutic Timeline

Clinical improvement may not be evident until 3 – 12 weeks after the initial dose or after any dose adjustment, according to evidence presented in the British Journal of Dermatology. 16

Management of Inadequate Response

If minimal efficacy is observed after 12 – 16 weeks of treatment, the recommendation is to consider switching to subcutaneous methotrexate or an alternative agent rather than continuing oral dose escalation, as reported in the British Journal of Dermatology. 16

Methotrexate Dosing and Monitoring in Disseminated Sarcoidosis

Initial Dosing Strategy

The multinational rheumatology guidelines endorse oral methotrexate 10–15 mg once weekly as a steroid‑sparing agent for disseminated sarcoidosis. 17
The 2021 European Respiratory Society (ERS) clinical practice guidelines list methotrexate as a standard immunosuppressive option with a typical starting dose of 10–15 mg once weekly. 18

Dose‑Escalation Protocol

Increase the weekly dose by 5 mg every 2–4 weeks based on clinical response and tolerability, aiming for a therapeutic range of 20–30 mg/week. 17
Rapid escalation (5 mg per month to reach 25–30 mg/week) provides greater efficacy but is associated with a higher incidence of gastrointestinal adverse events compared with slower escalation (5 mg every 3 months). 17

Route of Administration

Begin treatment with oral methotrexate; switch to subcutaneous or intramuscular administration if the highest tolerated oral dose fails to achieve adequate clinical response, if gastrointestinal intolerance occurs, or when doses exceed 20 mg/week because of reduced oral bioavailability. 17
Parenteral methotrexate offers higher bioavailability and may lessen gastrointestinal toxicity, although early rheumatoid‑arthritis trials reported a higher rate of treatment withdrawal due to toxicity. 17

Folic Acid Supplementation

Prescribe at least 5 mg of folic acid per week to mitigate gastrointestinal and hepatic toxicity without compromising methotrexate efficacy. 17
Weekly folic acid supplementation significantly reduces the risk of hepatotoxicity (odds ratio 0.17; 95 % CI 0.09–0.32). 19

Monitoring Requirements

Baseline Assessment

Prior to initiating methotrexate, obtain a complete blood count, liver enzymes (AST/ALT), albumin, serum creatinine, and a recent chest radiograph; also consider hepatitis B/C serology, HIV testing, fasting glucose, lipid profile, and a pregnancy test. 17

Ongoing Laboratory Monitoring

Monitor CBC, liver enzymes, and creatinine every 1–1.5 months until a stable dose is reached, then every 1–3 months thereafter. 17
Perform a clinical assessment for side‑effects and risk factors at each visit. 17

Management of Hepatotoxicity

Discontinue methotrexate if ALT or AST rise to >3 × the upper limit of normal on confirmed repeat testing; the drug may be re‑initiated at a lower dose after normalization of liver enzymes. 17

Safety Considerations

Methotrexate is considered appropriate for long‑term use in sarcoidosis owing to an acceptable safety profile demonstrated in guideline‑based evaluations. 17
The drug must be taken weekly; dosing errors (e.g., daily administration) are a major cause of life‑threatening toxicity. 17
Discontinue methotrexate at least three months before a planned pregnancy for both men and women; it is contraindicated during pregnancy and breastfeeding. 17
Avoid methotrexate in patients with significant renal impairment because the medication is primarily cleared renally. 18

Methotrexate Prescribing Guidelines

Pre‑treatment Evaluation

Obtain a baseline complete blood count to rule out significant thrombocytopenia, leukopenia, or anemia before initiating methotrexate. 20
Perform a pregnancy test in all individuals of child‑bearing potential prior to therapy. 20

Dosing and Administration

Pediatric inflammatory skin disease: Use weight‑based dosing up to 1 mg/kg/week, not exceeding 25 mg/week; test doses are unnecessary for low‑dose initiation. 21
Switch to parenteral formulation (subcutaneous or intramuscular) when oral therapy yields inadequate response, causes gastrointestinal intolerance, shows poor adherence, or when the weekly dose exceeds 20 mg. Parenteral routes provide higher bioavailability and may lessen gastrointestinal toxicity. 21

Folic Acid Supplementation

Prescribe daily folic acid (≈1 mg per day) on days other than the methotrexate dose to reduce hepatic abnormalities, nausea/vomiting, oral mucositis, fatigue, and headache without compromising efficacy. 21

Monitoring and Management of Abnormal Results

Liver enzymes: If alanine aminotransferase or aspartate aminotransferase rise to ≥ 3 × the upper limit of normal for two consecutive months, temporarily discontinue methotrexate. 21
Hematologic parameters: Discontinue or reduce the dose when total white‑blood‑cell count falls below 3 × 10⁹/L, absolute neutrophil count below 10 × 10⁹/L, or platelet count below 100 × 10⁹/L. 21

Contraindications

Absolute contraindications: Pregnancy, breastfeeding, cirrhosis, and pre‑existing significant cytopenias (thrombocytopenia, leukopenia, anemia). 20
Relative contraindication: Concomitant use of sulfonamide drugs and acitretin may be considered only with appropriate hepatic monitoring. 20

Special Populations

Pregnancy and Contraception

Stop methotrexate at least 3 months before planned conception for both males and females. 20
Require effective contraception for all individuals of child‑bearing potential while on therapy. 20
Teratogenic risk is highest during the first 6–8 weeks of gestation; fetal abnormalities have been reported at any gestational age. 20
Provide counseling on fetal loss and teratogenicity risks to all patients of reproductive potential. 21

High‑Risk Patients for Hepatotoxicity

In patients with prior exposure to hepatotoxic drugs or a family history of inheritable liver disease, continue methotrexate only when the estimated risk of cirrhosis is low. 22

Drug Interactions

Co‑administration of methotrexate with trimethoprim‑sulfamethoxazole is permissible and not contraindicated. 21
NSAIDs or salicylates may be given concurrently with low‑dose methotrexate in children who have normal renal function. 21

Discontinuation

Methotrexate can be stopped abruptly without withdrawal effects, although disease activity may worsen; tapering speed should be individualized based on disease severity, risk of flare, and patient preferences. 21